Saudamini Dabak is the Head of HITAP’s International Unit (HIU). She started working at HITAP as an Overseas Development Institute (ODI) Fellow in 2015. At HITAP, Saudamini has supported Health Technology Assessment (HTA) initiatives in Asia and Africa and has also been involved in conducting health systems research. Prior to working at HITAP, Saud

Sarinya SakthongJeen started work at HITAP on April 5, 2021 as financial officer. She started work on April 5, 2021. She graduated with a master’s degree, Business Administration from Sukhothai Thammathirat University, Bachelor’s Degree in General Business Management from Silpakorn University. She has over 12 years of banking experience in finance

Sarin KC is Head of the Environmental Economics Unit at HITAP, Ministry of Public Health, Thailand. Previously, he worked as a research analyst at the London School of Economics and Political Science (LSE) and the Ministry of Health and Population in Nepal.As a health economist, he has helped institutionalise Health Technology Assessment (HTA) in c

On 17th September 2018, Sarah Garner, coordinator of the Innovation, Access and Use team under the Essential Medicines and Health Products program, World Health Organization, had an informal meeting at the Health Intervention and Technology Assessment Program (HITAP). She was eager to learn about HI

HITAP, under the leadership of the National Health Foundation (NHF), Thailand, is partnering with the Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore (NUS) and the Mathematical/Economic Modelling Department (MAEMOD) at the Mahidol Oxford Tropical Medicine Research Unit (MORU) as part of the Asia HTA Consortium

(Reuters) – Sanofi’s experimental pill to treat Gaucher disease, a rare inherited condition, has met its main goal in a late-stage trial, the French drugmaker said on Tuesday.Patients treated with the drug, eliglustat tartrate, showed a statistically significant improvement in the size of their sple

(Reuters) – Sanofi’s rare disease unit Genzyme is pulling leukaemia drug Campath to prepare for its launch under a different dosage and as a multiple sclerosis treatment that will be branded as Lemtrada.The withdrawal, meant to prevent the off-label use of Campath as a multiple sclerosis drug, is al

Vietnam visit 30th and 31st May 2017It feels good to see familiar faces when you are in a new place and I felt the same meeting officials from Health Strategy Planning Institution (HSPI), Ministry of Health of Vietnam once again. I had met them earlier during the HTAsiaLink conference held in April

I (the author of the blog) got to learn a lot about three things while discussions on these potential topics were on-going. Firstly, I got to know the uniqueness of the Vietnamese Health System and how they are trying to incorporate HTA and pharmacoeconomics in their current system, secondly I learn

Ryan Jonathan Sitanggang is an International Cooperation Officer (ICO) at the International Unit of the HITAP Foundation. He works on strengthening HTA networks and systems across Asia through initiatives such as the Asia HTA Registry, the HTAsiaLink Strategic Plan, and regional capacity-building. His role includes managing partnerships, coordinati